China Universal Asset Management Co. Ltd. Has $69,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

China Universal Asset Management Co. Ltd. raised its stake in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 63.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 24,121 shares of the company’s stock after purchasing an additional 9,404 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Nautilus Biotechnology were worth $69,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of NAUT. Dimensional Fund Advisors LP boosted its holdings in shares of Nautilus Biotechnology by 19.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock worth $1,345,000 after buying an additional 94,908 shares during the period. Vanguard Group Inc. boosted its holdings in Nautilus Biotechnology by 1.0% during the first quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock valued at $8,407,000 after acquiring an additional 29,604 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Nautilus Biotechnology in the third quarter valued at about $50,000. Clarius Group LLC increased its stake in shares of Nautilus Biotechnology by 2.7% in the second quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock worth $1,489,000 after purchasing an additional 16,661 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Nautilus Biotechnology by 11.2% in the second quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after purchasing an additional 14,100 shares during the period. Institutional investors own 50.71% of the company’s stock.

Insider Buying and Selling at Nautilus Biotechnology

In other news, VP Mary E. Godwin sold 47,031 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $2.87, for a total transaction of $134,978.97. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 40.50% of the company’s stock.

Nautilus Biotechnology Stock Down 1.9 %

Shares of NASDAQ:NAUT opened at $2.60 on Friday. The business has a 50 day moving average price of $2.76 and a 200 day moving average price of $2.62. The company has a market cap of $326.07 million, a price-to-earnings ratio of -4.64 and a beta of 1.22. Nautilus Biotechnology, Inc. has a twelve month low of $2.19 and a twelve month high of $3.45.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. During the same period in the prior year, the firm earned ($0.13) earnings per share. Analysts anticipate that Nautilus Biotechnology, Inc. will post -0.65 EPS for the current year.

Nautilus Biotechnology Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.